Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of cancer that is advanced and/or metastatic.
Have disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST ) version 1.1.
Have adequate organ function.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Have discontinued previous treatments for cancer for at least 28 days or 5 half-lives prior to study enrolment.
You may not be if
Have serious preexisting medical conditions.
Have received treatment with a drug predominantly targeting Ang2 activity.
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Have current hematologic malignancies.
Have an active fungal, bacterial, and/or known viral infection.
Have a corrected QT interval using Fridericia's correction (QTcF) of \>470 msec on screening electrocardiogram (ECG) at several consecutive days of assessment.
Have a known sensitivity to mAbs or other therapeutic proteins.
Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.
Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 3 months prior to receiving treatment.
Receive anticoagulation therapy at therapeutic dose.
Have experienced any arterial or venothrombotic or thromboembolic events within 6 months prior to study treatment.
Have liver cirrhosis with a Child-Pugh class B or worse or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.
The participant is pregnant prior to randomization or breastfeeding.
The participant has sensory peripheral neuropathy ≥ Grade 2 (Part E only).
Clareo Health | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
